Novoron Bioscience’s CEO, Travis Stiles, Ph.D., to Present at the 2025 Biocom Global Life Science Partnering and Investor Conference

Novoron Bioscience, a pre-clinical biotechnology company developing novel therapeutics for degeneration or trauma of the brain and spinal cord, was selected to be a featured presenter at the 2025 Biocom Global Life Science Partnering and Investor Conference. This distinguished event is renowned for uniting world-class innovators, strategic investors, and leading partners in the life science industry, making it an unparalleled platform for showcasing breakthrough advancements.

“We are thrilled to be given the opportunity to showcase our exciting technology on such a prominent stage,” said Dr. Stiles. “Our participation at the conference not only underscores our commitment to advancing neurological therapeutics but will also serve as somewhat of a 'grand unveiling' of a program that we believe can be truly transformative in the dementia space.” With a robust pipeline of innovative therapies and a deep dedication to improving patient outcomes, Novoron Bioscience is poised to make a significant impact in the rapidly evolving field of neuroscience.

Novoron Bioscience looks forward to engaging with industry leaders and forging new partnerships that will drive the future of neuroscience innovation.

For further information, please contact:
Brett Drummond
Communications Manager
Novoron Bioscience
brett.drummond@novoron.com